Home
HelpTest ID RUFI Rufinamide, Serum
Useful For
Monitoring serum rufinamide concentrations, assessing compliance, and adjusting dosage in patients receiving other drugs which interact pharmacokinetically with rufinamide (ie, drugs that induce liver CYP3A4 enzymes) and may be helpful in who are receiving hemodialysis
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Rufinamide, SSpecimen Type
SerumContainer/Tube:
Preferred: Red top
Acceptable: SST
Specimen Volume: 1 mL
Collection Instructions:
1. Draw blood immediately before next scheduled dose.
2. For sustained-release formulations ONLY, draw blood a minimum of 12 hours after last dose.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 28 days |
| Ambient | 28 days | |
| Frozen | 28 days |
Clinical Information
Rufinamide is a new antiepileptic drug (AED) approved by the Food and Drug Administration as add-on treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children ≥4 years, and for the treatment of focal seizures in adults and adolescents. Its mechanism of action is not completely understood, but it is believed to work by prolonging the inactive state of sodium channels and therefore limiting excessive firing of sodium-dependent action potentials. The most commonly observed side effects are headache, dizziness, fatigue, somnolence, and nausea.
Reference Values
5.0-30.0 mcg/mL
Cautions
No significant cautionary statements
Day(s) Performed
Tuesday, Thursday, Saturday; 2 p.m.
Report Available
Same day/1 dayPerforming Laboratory
Mayo Medical Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
80339
G0480 (if appropriate)